Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
162 Leser
Artikel bewerten:
(0)

Region's First Double Hand Transplant Performed at Hospital of the University of Pennsylvania

Penn Medicine Surgeons Team, with Gift of Life, Extends Frontier of Life-Enhancing Surgery

PHILADELPHIA, Oct. 28, 2011 /PRNewswire-USNewswire/ -- For the first time in the Delaware Valley Region, a patient has undergone a complex and intricate transplant procedure that could significantly enhance the quality-of-life for persons with multiple limb loss.

Last month, a highly-skilled, specially-trained team from the newly established Penn Hand Transplant Program at the Penn Transplant Institute performed its first bilateral (double) hand transplant. Working closely with its partner, Gift of Life Donor Program, a team of 30 members - 12 surgeons, three anesthesiologists and 15 nurses - performed the 11-and-a-half hour double transplant procedure - a Vascularized Composite Allotransplantation - that involved experts in solid organ transplantation, orthopaedic surgery, plastic surgery, reconstructive microsurgery and anesthesia.

Details of this history-making procedure will be forthcoming at a press conference to be held at the Hospital of the University of Pennsylvania.

WHEN:
Tuesday, November 1, 2011
10 a.m.


WHERE:
The Hospital of the University of Pennsylvania
Flyers/76ers Theatre
Ravdin Building, Ground Floor
34th & Spruce Streets
Philadelphia, PA 19104
Media should enter the Main Entrance of HUP on 34th Street
Once inside the Main Ravdin Lobby make a right
Theatre down the hall on the right


WHO:
L. Scott Levin, M.D., FACS.
Director, Penn Hand Transplant
Chair, Department of Orthopaedic Surgery
Paul B. Magnuson Professor of Bone and Joint Surgery
Professor of Surgery, Division of Plastic Surgery


Benjamin Chang, M.D.
Co-director, Penn Hand Transplant
Program Director and Associate Chief, Division of Plastic Surgery
Associate Professor of Clinical Surgery


Richard D. Hasz
Vice President, Clinical Services
Gift of Life Donor Program


Abraham Shaked, M.D., Ph.D.
Director, Penn Transplant Institute
Vice Chairman, department of Surgery
Eldridge L. Eliason Professor of Surgery

Arthur L. Caplan, Ph.D. (Via Prerecorded Interview)
Director, Center for Bioethics
Professor, Medical Ethics


Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4 billion enterprise.

Penn's Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools and among the top 10 schools for primary care. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $507.6 million awarded in the 2010 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital - the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2010, Penn Medicine provided $788 million to benefit our community.

Gift of Life: Since 1974, Gift of Life has served as the link between donors and patients awaiting life-saving transplants in the eastern half of Pennsylvania, southern New Jersey and Delaware. Gift of Life Donor Program is the nation's most active and well-respected organ procurement organization, coordinating more than 32,000 life-saving organ transplants and hundreds of thousands of tissued transplants during the last 37 years. For more information on organ and tissue donation, please call the Gift of Life at 1-800-DONORS-1 or visit its website, www.donors1.org.

This news release was issued on behalf of Newswise. For more information, visit http://www.newswise.com.

SOURCE Hospital of University of Pennsylvania

© 2011 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.